Dear Editor:

There is more and more accumulated evidence that questions the safety of treatment with tumor necrosis factor (TNF) antagonists regarding the development of tuberculosis (TB). Although we have more data available on the risk for TB in patients treated with etanercept and infliximab, and since we have no TB risk contacts, treatment for latent tuberculosis infection (LTI) was not indicated. One month after the start of the treatment, the patient consulted for a symptoms evolving over 3 weeks by low fever, asthenia and anorexia, with no additional cough or expectoration. He had been receiving treatment with ciprofloxacin for 1 week, with no improvement. On chest radiograph, pleural effusion was observed up until the half of the right hemithorax, accompanied by low fever, asthenia and anorexia, with no additional cough or expectoration. He had been receiving treatment with ciprofloxacin for 1 week, with no improvement. On chest radiograph, pleural effusion was observed up until the half of the right hemithorax, accompanied by segmental alveolar infiltrates in the upper left lobe. The study of the pleural liquid revealed: uncomplicated, predominately lymphocytic exudate (65%); ADA 82 U/l; negative smear, Ziehl–Neelsen stain and PCR for mycobacteria; negative bacteria in an intradermal tuberculin test. A Mantoux test confirmed the presence of M. tuberculosis complex, sensitive to all drugs. The patient was treated with antituberculosis drugs, and adalimumab was withdrawn with no immediate complications. During follow-up, the patient presented an episode of interstitial nephritis secondary to adalimumab, which was resolved after the withdrawal of the drug.

Anti–TNF drugs, such as etanercept, infliximab and adalimumab, are fundamental in the treatment of inflammatory diseases, but the relative risk for TB increases between 1.6 and 25 times with this treatment, depending on the clinical context, the drug used and the country of origin. The rate of TB in patients treated with anti–TNF is 3–4 times greater in those who receive infliximab and adalimumab than in those receiving etanercept. LTI treatment with isoniazid for 9 months is adequate in patients with a positive tuberculin test, a chest radiograph suggesting disease or if there has been close contact with a case of tuberculosis. These guidelines have been shown to diminish in 80% the incidence of TB in our country. Our patient developed tuberculosis with pleural affection, despite following the recommendations for TB presentation by the Spanish Society of Rheumatology, therefore it is of interest to provide more evidence in addition to what has been recently reported about the complications of treatment with adalimumab. Although the time elapsed from the introduction of adalimumab until the onset of the symptoms could make us contemplate reactivation, a negative Mantoux at the start of the treatment would rule this out. The introduction of the diagnostic method based on in vitro production of interferon gamma in response to M. tuberculosis antigens (interferon–gamma release assay [IGRA]) would be especially useful in patients in whom negative tuberculin test should not rule out a latent infection, distinguishing true positives from the false positives caused by anti–tuberculosis vaccination.

We pulmonologists have a new challenge in controlling TB: patients who use anti–TNF drugs. The implementation of the new LTI diagnostic techniques would be of great use for this purpose.

References